Navigation Links
inVentiv Selling Solutions Selected to Provide Sales Team for Cephalon Inc.

SOMERSET, N.J., March 6 /PRNewswire-FirstCall/ -- inVentiv Selling Solutions, a division of inVentiv Health (Nasdaq: VTIV) and the industry leader in outsourced sales teams to the pharmaceutical industry, announced today that it has signed a contract with Cephalon Inc. to provide a sales team to support Amrix, Cephalon's once-daily extended-release muscle relaxant. In connection with this deployment, the company will also provide a variety of complementary services to support the sales program.

In addition to representing Cephalon, inVentiv Selling Solutions will use the same sales team to detail other, yet-to-be-identified products in the primary care market.

"inVentiv has a relationship with Cephalon that spans several of our companies and divisions. We are thrilled to be expanding that relationship by providing a sales team to support Amrix," said Paul Mignon, President of inVentiv Selling Solutions. "We look forward to putting our experience and our therapeutic expertise to work on behalf of this important product."

"inVentiv has an impressive track record and they've demonstrated a great willingness to work with us to help us achieve our goals," said Michael S. Mulholland, Senior Vice President, U.S. Pharmaceutical Operations at Cephalon, Inc. "We are very pleased to be partnering with them on this initiative."

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. The company's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA(R) (fentanyl buccal tablet) [C-II], TRISENOX(R) (arsenic trioxide) injection, AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at or by calling 1-800-896-5855.

About inVentiv Health

inVentiv Health, Inc. (Nasdaq: VTIV) is an insights-driven global healthcare leader that provides dynamic solutions to deliver customer and patient success. inVentiv delivers its customized clinical, sales, marketing and communications solutions through its four core business segments: inVentiv Clinical, inVentiv Communications, inVentiv Commercial, and inVentiv Patient Outcomes. inVentiv Health's client roster is comprised of more than 325 leading pharmaceutical, biotech, life sciences and healthcare payor companies, including all top 20 global pharmaceutical manufacturers. For more information, visit

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause inVentiv Health's performance to differ materially. Such risks include, without limitation: changes in trends in the pharmaceutical industry or in pharmaceutical outsourcing; our ability to compete successfully with other services in the market; our ability to maintain large client contracts or to enter into new contracts; uncertainties related to future incentive payments; and, our ability to operate successfully in new lines of business. Readers of this press release are referred to documents filed from time to time by inVentiv Health Inc. with the Securities and Exchange Commission for further discussion of these and other factors.

SOURCE inVentiv Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. inVentiv Health to Present at the 20th Annual Bear Stearns Healthcare Conference
2. inVentiv Health to Announce Third Quarter Results and Conduct Conference Call on Wednesday, November 7, 2007
3. inVentiv Health Launches Fourth Business Segment: inVentiv Patient Outcomes
4. inVentiv Health to Present at the 2007 Credit Suisse Healthcare Conference
5. inVentiv Health Creates Client Development and Integration Team
6. inVentiv Health Provides Updated Information on December 11th Investor Day
7. inVentiv Health to Announce Fourth Quarter and Full Year 2007 Results and Conduct Conference Call on Thursday, February 28th
8. inVentiv Health Ranked #17 by Training Magazine in its 2008 List of Top 125 Training Companies
9. inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007
10. Federal Trade Commission Attempts To Suppress Best-Selling Authors First Amendment Rights
11. FTC Attacks Infomercial Marketer to Silence Best-Selling Authors Weight-Loss Tips
Post Your Comments:
(Date:11/27/2015)... Wilmington, DE (PRWEB) , ... November 27, 2015 ... ... a member of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as ... is an independent group of Microsoft Dynamics SL software users, partners, industry experts ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping ... platform for mental health and wellness consultation, has collaborated with a leading web-based ... the knowledge gap experienced by parents and bring advice from parenting experts within ...
(Date:11/27/2015)... ... 2015 , ... Dr. Thomas Dunlap and Dr. Patrick Coleman ... with Emergency Medicine at St., Joseph Health System’s Santa Rosa Memorial Hospital , ... in similar ways and require time-critical intervention to avoid large area heart damage and ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... in central Michigan, have come together on Thanksgiving Day to share the things ... for viewing on the Serenity Point YouTube channel, patients displayed what they wrote ...
(Date:11/26/2015)... VA (PRWEB) , ... November 26, 2015 , ... ... an American Express Travel Representative. As a franchise owner, Somu now offers travelers, ... of cruise, destination wedding packages, private cruise sales, as well as, cabin upgrades ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... , Nov. 26, 2015 ... addition of the "2016 Global Tumor ... Country Volume and Sales Segment Forecasts, Innovative ... report to their offering. --> ... of the "2016 Global Tumor Marker ...
(Date:11/26/2015)... 26 november 2015 AAIPharma Services ... geplande investering aan van ten minste $15,8 ... en het mondiale hoofdkantoor in ... resulteren in extra kantoorruimte en extra capaciteit ... groeiende behoeften van de farmaceutische en biotechnologische ...
(Date:11/26/2015)... -- --> --> Juntendo ... optimal contrast weighting of MRI for patients with Multiple ... research agreement with SyntheticMR in order to use SyMRI in ... possible to generate multiple contrast images from a single scan ... thus making it possible to both fine tune images and ...
Breaking Medicine Technology: